Allergic diseases are a socially significant problem of global importance. The number of
people suffering from pollen allergies has increased dramatically in recent decades. Pollen …

Methods Mice transgenic for the human leukocyte antigen DRB1* 0401 were sensitized to
peanut epicutaneously and then treated with Ara h 1 peptides. Mice were subsequently …

Background: There is a need to improve the safety and efficacy of allergen-specific
immunotherapy. Long synthetic peptide-based immunotherapy was proven safe …

Sublingual immunotherapy (SLIT) has been introduced as a noninvasive and safer
approach for allergen-specific immunotherapies. In this study we investigated the efficacy of …

Worldwide more than 200 million individuals are allergic to group 1 grass pollen allergens.
We have used the major timothy grass pollen allergen Phl p 1, which cross‐reacts with most …

Allergen-specific immunotherapy is currently based on the administration of allergen
extracts containing natural allergens. However, its broad application is limited by the poor …

Allergen-specific immunotherapy (AIT) is a promising therapeutic approach to food allergy
but requires optimization in terms of both efficacy and safety due to the risk of undesired …

Background BM32, a grass pollen allergy vaccine containing four recombinant fusion
proteins consisting of hepatitis B-derived PreS and hypoallergenic peptides from the major …

Background Pollens, particularly tree and plant pollens, are one of the major causes of
allergic respiratory diseases worldwide. Allergy to pollens of different species of Salix trees …

Highlights What are the main findings? A peptide consisting of 20 amino acids was
designed in silico as a grass pollen allergy vaccine. The epitope-based vaccine has been …